https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-14 08:18:272022-12-14 08:18:27Poolbeg exclusively licences innovative oral delivery technology for metabolic syndrome related diseases
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-14 08:09:412022-12-14 08:09:41STORM Therapeutics announces closing of USD $30M Series B financing
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-13 08:10:522022-12-13 08:10:52Another Award for Synaffix: ‘Business Development Team of Year’ at the Scrip Awards
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-13 07:03:092022-12-13 07:03:09Futura Medical provide update on a milestone year of regulatory and commercial progress for MED3000
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-12 10:33:382022-12-12 10:33:38CellCentric presents early clinical data at ASH
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-12 08:02:192022-12-12 10:25:09Poolbeg Pharma plc. POLB 001 LPS human challenge clinical trial successfully completed. No serious adverse events reported. Results of full data analysis expected in Q2 2023
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
Marketing Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Marketing Team2022-12-07 09:03:062022-12-07 09:03:06Neuraxpharm expands into the Netherlands
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-06 08:35:532022-12-06 08:35:53ImaginAb Announces new Clinical Trial at Hull University Teaching Hospitals NHS Trust to Investigate CD8 ImmunoPET in Patients with Renal Cancer and Malignant Melanoma
https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos.png
180
300
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-01 15:49:362023-06-14 15:50:15LSX and Jefferies – Insights from the busiest week in European biotech
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-11-30 08:47:052022-11-30 08:47:05ISA Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal Cancer
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-11-30 08:46:422022-12-07 09:05:56NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
Marketing Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Marketing Team2022-11-29 09:27:572022-11-29 09:27:57Biocomposites adds Mexico to its list of countries where STIMULAN is approved as an antibiotic carrier for use in bone and soft tissue
https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos.png
180
300
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-11-23 15:59:262023-06-14 15:50:31Panel Summaries from Optimum’s 14th Annual Healthcare Investor Conference 2022
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
Marketing Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Marketing Team2022-11-23 09:06:472022-11-23 09:06:47STORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
Marketing Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Marketing Team2022-11-22 10:29:482022-11-22 10:29:48ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with TriSalus Life Sciences
https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos.png
180
300
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-11-17 09:07:492023-06-14 15:50:43Dan Mahony & Gareth Powell – Global healthcare investing: Can hindsight hone the crystal ball for the future? A fireside chat moderated by Amy Brown, Evaluate Vantage
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-11-16 10:02:472022-11-16 10:02:47Synaffix Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
Marketing Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Marketing Team2022-11-15 15:42:422022-11-15 15:42:42ImaginAb Executes License and Supply Agreement for CD8 ImmunoPET Technology with DynamiCure Biotechnology
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-11-15 10:43:162022-11-15 10:43:16Destiny Pharma plc – XF-73 Dermal infection project advances into clinically enabling safety study as part of ongoing agreement with US Government’s NIAID
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-11-15 09:00:002022-11-15 09:00:00Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKONFor more information about Optimum Strategic Communications, please get in touch.
